Former Pfizer Inc. CEO Jeffrey Kindler’s abrupt resignation on Dec. 5 came just in time to give the feds what they wanted: a new leadership structure at the drug giant.

While accepting Kindler’s resignation, the board of directors suddenly reversed its longstanding stance on corporate structure — announcing that Kindler’s replacement would hold the CEO job only, and that a new chairman of the board would be named later.